J. Goldman & Co’s Erasca ERAS Stock Holding History

J. Goldman & Co’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-98,033	Closed	-$1.59M	–	769
2026 Q1	$1.59M	Buy	+98,033	New	+$1.16M	0.05%	361

Other funds holding ERAS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

J. Goldman & Co's ERAS Position: Q2 2026 in Review

J. Goldman & Co sold out of Erasca (ERAS) in Q2 2026, closing a stake of 98,033 shares — an estimated $1.59M sold.

J. Goldman & Co first reported a position in ERAS in Q1 2026 and held it in 1 quarter. The position peaked at $1.59M in Q1 2026. 256 funds tracked by Wall St. Rank hold ERAS as of Q2 2026.

J. Goldman & Co reported no remaining Erasca position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 98,033 Erasca shares in Q2 2026, an estimated $1.59M.
J. Goldman & Co first reported a position in Erasca in Q1 2026 and held it in 1 quarter.
J. Goldman & Co's Erasca position peaked at $1.59M in Q1 2026.
256 funds tracked by Wall St. Rank held Erasca as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.